Adagene (ADAG) Stock Price, News & Analysis

Company Overview

Adagene Inc. is a biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies. The company combines computational methods, antibody engineering and translational research to create medicines designed to address limitations associated with conventional immuno-oncology treatments.

Adagene’s technology platform includes NEObody, which is intended to identify antibodies with differentiated binding characteristics, and SAFEbody, a masking technology designed to conditionally activate antibodies in the tumor microenvironment. These platforms support the company’s efforts to develop therapies directed at immune-regulatory targets, including programs involving checkpoint and costimulatory pathways.

Founded in 2017, Adagene has operated with a research and development presence in both the United States and China, serving the global biopharmaceutical market. The company was co-founded and led by Peter Luo, who has served as chief executive officer. Its work has included internal drug development as well as collaborations intended to advance antibody therapeutics.

Key Stats

• Today's Range: $2.44 to $2.73
• 50-Day Range: $2.74 to $4.23
• 52-Week Range: $1.30 to $4.85
• Volume: 228,526 shs
• Average Volume: 244,197 shs
• Market Capitalization: $162.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Moderate Buy

Adagene Stock Analysis - MarketRank™

Adagene scored higher than 78% of companies evaluated by MarketBeat, and ranked 131st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adagene has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Adagene has a consensus price target of $8.67, representing about 241.2% upside from its current price of $2.54.

Amount of Analyst Coverage

Adagene has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adagene are expected to grow in the coming year, from ($0.50) to ($0.45) per share.

Price to Book Value per Share Ratio

Adagene has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.06% of the float of Adagene has been sold short.

Short Interest Ratio / Days to Cover

Adagene has a short interest ratio ("days to cover") of 7.47.

Change versus previous month

Short interest in Adagene has recently increased by 0.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adagene does not currently pay a dividend.

Dividend Growth

Adagene does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.05

News Sentiment

Adagene has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Adagene this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ADAG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Adagene in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $162,258.00 in company stock, which represents 0.0967% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Adagene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $162,258.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.51% of the stock of Adagene is held by institutions.

Company Calendar

• Last Earnings: 4/01/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ADAG
• CIK: 1818838
• Web: www.adagene.com
• Phone: 86-512-8777-3632
• Fax: N/A
• Employees: 128
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Adagene: $8.67
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +252.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.02
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $7.67 million
• Price / Sales: 21.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.75 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 66,050,000
• Free Float: 52,049,000
• Market Cap: $162.48 million
• Optionable: Not Optionable
• Beta: 0.54